PIRS News and Press, Pieris Pharmaceuticals Inc. From 09/20/20

Clinical benefit in both trials, including one confirmed complete response and three partial responses in the monotherapy trial and four confirmed partial responses in the atezolizumab combination trial Robust durability of response in both trials, including more than 18 months in the...

Will These High Volume Penny Stocks Make Higher Highs This Month? One of the quickest ways to find penny stocks is by looking at technical trends. As I’ve said in the past, sometimes volume and price will dictate momentum before fundamentals. While that type of action could stem from...

Pieris Pharmaceuticals, Inc. (PIRS) Q2 2020 Earnings Conference Call August 10, 2020 08:00 AM ET Company Participants Tom Bures - Vice President of Finance Steve Yoder - President and Chief Executive Officer Ingmar Bruns - Senior Vice President and Head of Clinical Development ...

Company to Host an Investor Conference Call on Monday, August 10, 2020 at 8:00 AM EDT PRS-060/AZD1402 phase 2a trial in asthma to start in fourth quarter Signed clinical trial collaboration agreement with Lilly for supply of ramucirumab for phase 2 trial of PRS-343 PRS-343 ph...

Pieris Pharmaceuticals (NASDAQ: PIRS )  has entered into a clinical trial collaboration and supply agreement with Eli Lilly (NYSE: LLY ) to evaluate the safety and efficacy of combining Pieris' PRS-343, a 4-1BB/HER2 bispecific for HER2-positive tumors, with Lilly's ramucirumab, a V...

BOSTON, MA / ACCESSWIRE / August 10, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, toda...

BOSTON, MA / ACCESSWIRE / August 3, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer and other indications, today announced ...

BOSTON, MA / ACCESSWIRE / July 23, 2020 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS) , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin ® technology platform for respiratory diseases, cancer, and other indications, today announce...

The FDA has instituted a partial clinical hold on Phase 1 clinical trials of Pieris Pharmaceuticals' (NASDAQ: PIRS ) lead candidate PRS-343 until the company conducts an additional in-use and compatibility study with various infusion materials under specific conditions aimed at confirmin...

FDA requested a confirmatory laboratory-based in-use and compatibility study before enrolling new patients Currently-enrolled patients may continue to receive PRS-343 In its telephonic communication, FDA did not cite any adverse events in connection with its request Company ...